Imaging behavior of the normal adrenal on ferumoxytol-enhanced MRI: Preliminary findings

American Journal of Roentgenology

Volumn 201, Issue 1, 2013, Pages 117-121

  Gunn, Andrew J ^a   Seethamraju, Ravi T ^b   Hedgire, Sandeep ^a   Elmi, Azadeh ^a   Daniels, Gilbert H ^a   Harisinghani, Mukesh G ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Hlth Serv Research and Development   (United States)

Author keywords

Adrenal; Ferumoxytol; Ultrasmall superparamagnetic iron oxide nanoparticles (USPIOs)

Indexed keywords

FERUMOXYTOL;

ADRENAL GLAND; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; IMAGE ANALYSIS; IMAGE ENHANCEMENT; INTERMETHOD COMPARISON; LIVER; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PANCREAS; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; SIGNAL NOISE RATIO; SKELETAL MUSCLE; SPLEEN;

ADENOCARCINOMA; ADRENAL GLANDS; ADULT; AGED; AGED, 80 AND OVER; CONTRAST MEDIA; FEMALE; FERROSOFERRIC OXIDE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; REFERENCE VALUES; SIGNAL-TO-NOISE RATIO;

EID: 84883400016     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.12.9357     Document Type: Article

References (23)

1. Weissleder R, Elizondo G, Wittenberg J, Rabito CA, Bangele HH, Josephson L. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agent for MR imaging. Radiology 1990; 175:489-493
2. McLachlan SJ, Morris MR, Lucas MA, et al. Phase I clinical evaluation of a new iron oxide MR contrast agent. J Magn Reson Imaging 1994; 4:301-307
3. Weinstein JS, Varallyay CG, Dosa E, et al. Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. J Cereb Blood Flow Metab 2010; 30:15-35
4. Anzai Y, McLachlan S, Morris M, Saxon R, Lufkin RB. Dextran-coated superparamagnetic iron oxide, an MR contrast agent for assessing lymph nodes in the head and neck. AJNR 1994; 15:87-94
5. Anzai Y, Blackwell KE, Hirschowitz SL, et al. Initial clinical experience with dextran-coated superparamagnetic iron oxide for detection of lymph node metastases in patients with head and neck cancer. Radiology 1994; 192:709-715
6. Weissleder R, Guillermo E, Wittenberg J, Lee AS, Josephson L, Brady TJ. Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MRI. Radiology 1990; 175:494-498
7. Hudgins PA, Anzai Y, Morris MR, Lucas MA. Ferumoxtran-10, a superparamagnetic iron oxide as a magnetic resonance enhancement agent for imaging lymph nodes: a phase 2 dose study. AJNR 2002; 23:649-656
8. Bourrinet P, Bengele HH, Bonnemain B, et al. Preclinical safety and pharmacokinetic profile of ferumoxtran-10, an ultrasmall superparamagnetic iron oxide magnetic resonance contrast agent. Invest Radiol 2006; 41:313-324
9. Enochs WS, Harsh G, Hochberg F, Weissleder R. Improved delineation of human brain tumors on MR images using a long-circulating, superparamagnetic iron oxide agent. J Magn Reson Imaging 1999; 9:228-232
10. Varallyay P, Nesbit G, Muldoon LL, et al. Comparison of two superparamagnetic viral-sized iron oxide particles ferumoxides and ferumoxtran-10 with a gadolinium chelate in imaging intracranial tumors. AJNR 2002; 23:510-519
11. Saksena M, Harisinghani M, Hahn P, et al. Comparison of lymphotropic nanoparticle-enhanced MRI sequences in patients with various primary cancers. AJR 2006; 187:[web]W582-W588
12. Harisinghani MG, Saksena M, Ross RW, et al. A pilot study of lymphotrophic nanoparticle-enhanced magnetic resonance imaging technique in early stage testicular cancer: a new method for noninvasive lymph node evaluation. Urology 2005; 66:1066-1071
13. Li CS, Harisinghani MG, Lin WC, Braschi M, Hahn PF, Mueller PR. Enhancement characteristics of ultrasmall superparamagnetic iron oxide particle within the prostate gland in patients with primary prostate cancer. J Comput Assist Tomogr 2008; 32:523-528
14. Guimaraes AR, Tabatabei S, Dahl D, McDougal WS, Weissleder R, Harisinghani MG. Pilot study evaluating use of lymphotrophic nanoparticle-enhanced magnetic resonance imaging for assessing lymph nodes in renal cell cancer. Urology 2008; 71:708-712
15. Tabatabaei S, Harisinghani M, McDougal WS. Regional lymph node staging using lymphotrophic nanoparticle enhanced magnetic resonance imaging with ferumoxtran-10 in patients with penile cancer. J Urol 2005; 174:923-927
16. Rockall AG, Sohaib SA, Harisinghani MG, et al. Diagnostic performance of nanoparticle-enhanced magnetic resonance imaging in the diagnosis of lymph node metastases in patients with endometrial and cervical cancer. J Clin Oncol 2005; 23:2813-2821
17. Saokar A, Gee MS, Islam T, Mueller PJ, Harisinghani MG. Appearance of primary lymphoid malignancies on lymphotropic nanoparticle-enhanced magnetic resonance imaging using ferumoxtran-Clin Imaging 2010; 34:448-452
18. Tanabe M, Ito K, Shimizu A, et al. Hepatocellular lesions with increased iron uptake on superparamagnetic iron oxide-enhanced magnetic resonance imaging in cirrhosis or chronic hepatitis: comparison of four magnetic resonance sequences for lesion conspicuity. Magn Reson Imaging 2009; 27:801-806
19. Harisinghani M, Ross RW, Guimaraes AR, Weissleder R. Utility of a new bolus-injectable nanoparticle for clinical cancer staging. Neoplasia 2007; 9:1160-1165
20. MacDonald R, Mallory GK. Hemochromatosis and hemosiderosis: study of 211 autopsied cases. Arch Intern Med 1960; 105:686-700
21. Drakonaki E, Papakonstantinou O, Maris T, Vasilladou A, Papadakis A, Gourtsoyiannis N. Adrenal glands in beta-thalassemia major: magnetic resonance (MR) imaging features and correlation with iron stores. Eur Radiol 2005; 15:2462-2468
22. Thomas JP. Aldosterone deficiency in a patient with idiopathic haemochromatosis. Clin Endocrinol (Oxf) 1984; 21:271-277
23. Cantin M, Benchimol S. Localization and characterization of carbohydrates in adrenal medullary cells. J Cell Biol 1975; 65:463-469